Zelluna ASA
Research Zelluna ASA (ZLNA) on Bullrun: market cap NOK 655.93M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZLNA
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 655.93M
- Financial periodQ1 2026
- RevenueNOK 0
- Net income-NOK 20.37M
- Free cash flow-NOK 28.59M
Valuation Snapshot
latest market cap is NOK 655.93M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | NOK 0 | -NOK 139.75M | -NOK 149.88M | n/a | -9.2 | NOK 12.63M | NOK 0 | NOK 300.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | NOK 655.93M | n/a | n/a | n/a |
About Zelluna ASA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zelluna ASA's market cap?
Zelluna ASA's market capitalization is NOK 655.93M.
What does Zelluna ASA do?
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.